



รายงานการวิจัย

การติดเชื้อ *Helicobacter pylori* ที่กระเพาะอาหารในหนูที่เป็นโรค lupus nephritis จากการขาด FcγRIIb ทำให้โรคลุบัสมีความรุนแรงมากขึ้น

Helicobacter pylori infection increased anti-dsDNA and enhanced lupus severity in symptomatic FcγRIIb-deficient lupus mice

ผศ.ดร.นพ. อัมภาศ สีสหวนิชกุล

คณะแพทยศาสตร์ จุฬาลงกรณ์มหาวิทยาลัย

ACKNOWLEDGEMENT

This research is funded by Chulalongkorn University.

บทคัดย่อภาษาไทย

การติดเชื้อ *Helicobacter pylori* ที่กระเพาะอาหาร(ทำให้เกิดโรคแผลในกระเพาะอาหารเรื้อรัง) เป็นโรคที่พบบ่อยในประชากรเอเชียตะวันออกเฉียงใต้ ในขณะที่เดียวกันโรคพุ่มพวง (ลูปัส) ก็เป็นโรคทางภูมิคุ้มกันที่พบบ่อยมากในประชากรดังกล่าวเช่นเดียวกัน ซึ่งบางส่วนเนื่องมาจากการขาดการทำงานของยีน FcγRIIb ที่มีหน้าที่ในการยับยั้งการตอบสนองทางภูมิคุ้มกัน ดังนั้นจึงเป็นที่น่าสนใจว่าผู้ป่วยลูปัสที่เกิด การติดเชื้อ *Helicobacter pylori* จะเกิดลักษณะเช่นไร

ผู้วิจัยจึงได้ใช้หนูทดลองที่เกิดโรคลูปัสจากการขาดตัวยับยั้งทางพันธุกรรม คือ หนูที่ขาดยีน FcγRIIb (FcγRIIb^{-/-}) ที่เกิดอาการลูปัสแล้ว (มีอายุ 6 เดือน) มาทำให้เกิดการติดเชื้อ *Helicobacter pylori* เป็นที่น่าสนใจว่าความรุนแรงของโรคลูปัส (โปรตีนรั่วในปัสสาวะ และ ค่าการทำงานของไต) การพบ anti-dsDNA พบได้มากกว่ามากกว่าในหนู FcγRIIb^{-/-} ที่เกิดการติดเชื้อ *Helicobacter pylori* โดยความรุนแรงของการติดเชื้อ *Helicobacter pylori* ในหนู FcγRIIb^{-/-} นั้นไม่แตกต่างจากหนูปกติ โดยหนูทั้งสองกลุ่มมีน้ำหนักลดใกล้เคียงกัน อย่างไรก็ดี หนู หนู FcγRIIb^{-/-} ที่เกิดการติดเชื้อ *Helicobacter pylori* นั้นมีม้ามขนาดใหญ่ขึ้นจากการพบเซลล์ที่ทำหน้าที่ ในการสร้าง antibody (เช่น activated B cell, plasma cell and follicular helper T cell) มากกว่า หนูปกติที่เกิดการติดเชื้อ การสร้าง แอนติบอดี ที่มากขึ้นนั้น ทำให้ มี circulating immune complex เกาะตามอวัยวะต่างๆมากขึ้น เกิด anti dsDNA ที่สูงขึ้น มีการเกาะของ immune complex ที่ glomeruli มากขึ้น ส่งผลให้เกิดความรุนแรงของโรคลูปัสที่มากขึ้น นอกจากนั้นพบว่า ความสามารถในการจับกินและการฆ่าเชื้อของแมคโครเฟสนั้นลดลง ในภาวะที่เกิด immune complex ในปริมาณที่มากขึ้น

ผู้วิจัยสรุปว่า การติดเชื้อ *Helicobacter pylori* ในภาวะลูปัสที่เกิดอาการแล้วนั้น ทำให้ความรุนแรงของโรคลูปัสมากขึ้น ในทางคลินิก คนไข้ลูปัสที่มีอาการปวดท้องเรื้อรัง ม้ามโต ไสโตคายต์ ในเลือดสูงโดยไม่ทราบสาเหตุ หรือ ผู้ที่เกิดการติดเชื้อ *Helicobacter pylori* นั้น อาจจะมีการกำเริบของโรคได้ เนื่องจากการเกิดการอักเสบเรื้อรังจากเชื้อในกระเพาะอาหาร ดังนั้น ผู้ป่วยลูปัสที่เกิดอาการทางระบบทางเดินอาหารที่อาศัยอยู่ในแหล่งระบาดของ *Helicobacter pylori* ความให้ควมระมัดระวังในการเกิดภาวะการอักเสบเรื้อรัง ที่อาจจะทำให้เกิดโรคลูปัสที่มีความรุนแรงขึ้นได้ การศึกษาเพิ่มเติมในหัวข้อนี้มีความน่าสนใจ

Abstract

The defect on Fc gamma receptor IIb (Fc γ RIIb), the only inhibitory Fc γ R, has been identified as one of the genetic factors increasing susceptibility to lupus. The prevalence of *Helicobacter pylori* (HP) and Fc γ RIIb dysfunction-polymorphisms are high among Asians, and their co-existence is possible. Unfortunately, the influence of HP against lupus progression in patients with lupus is still controversial. In this study, the interactions between these conditions were tested with HP infection in 24-week-old Fc γ RIIb^{-/-} mice (symptomatic lupus). HP induced failure to thrive, increased stomach bacterial burdens and stomach injury (histology and cytokines) in both wild type and Fc γ RIIb^{-/-} mice. While the severity of HP infection, as determined by these parameters, was not different between both strains, antibodies production (anti-HP, anti-dsDNA and serum gammaglobulin) were higher in Fc γ RIIb^{-/-} mice compared to wild type. Accordingly, HP infection also accelerated the severity of lupus as determined by proteinuria, serum creatinine, serum cytokines, renal histology, and renal immune complex deposition. Although HP increased serum cytokines in both wild type and Fc γ RIIb^{-/-} mice, the levels were higher in Fc γ RIIb^{-/-} mice. As such, HP also increased spleen weight and induced several splenic immune cells responsible for antibody productions (activated B cell, plasma cell and follicular helper T cell) in Fc γ RIIb^{-/-} mice, but not in wild type. These data describe the different systemic responses against localized HP infection from diverse host genetic background. In conclusion, the mutual interactions between HP and lupus manifestations of Fc γ RIIb^{-/-} mice were demonstrated in this study. With the prominent immune responses from the loss of inhibitory signaling in Fc γ RIIb^{-/-} mice, HP infection in these mice induced intense chronic inflammation, increased antibody production, and enhanced lupus severity. Thus, the increased systemic inflammatory responses due to localized HP inducing gastritis in some patients with lupus may enhance lupus progression. More studies are needed

สารบัญเรื่อง (TABLE OF CONTENTS)

บทคัดย่อภาษาไทย.....	1
Abstract.....	2
สารบัญเรื่อง (TABLE OF CONTENTS).....	3
สารบัญภาพ (List of Illustration)	5
คำอธิบายสัญลักษณ์และคำย่อที่ใช้ในการวิจัย (LIST OF ABBREVIATIONS).....	6
ส่วนประกอบเนื้อเรื่อง	7
บทนำ (Introduction).....	7
เนื้อเรื่อง (Materials and Methods).....	8
Animal and animal model.....	8
<i>Helicobacter pylori</i> Administration Model.....	8
Urease Test, a Semi-Quantitative Analysis of Gastric <i>Helicobacter pylori</i> Burden.....	9
Polymerase Chain Reaction (PCR), a Quantitative Analysis of Gastric <i>Helicobacter pylori</i> Burden	9
Direct Culture, a Quantitative Analysis of Gastric <i>Helicobacter pylori</i> Burden	9
Stomach Histology and Anti- <i>Helicobacter pylori</i> Antibody.....	10
Cytokines Measurements in Gastric Tissues and Serum	10
Lupus Characteristics (Anti-dsDNA, Proteinuria, Serum Creatinine, and Renal Histology).....	10
An Analysis of Serum Gamma Globulin	11
Flow Cytometry Analysis of Spleen	11
Macrophages Phagocytosis and Macrophage Killing Activity.....	12
Statistical Analysis	13
Result (ผลการทดลอง).....	13

The Prominent Anti- <i>Helicobacter pylori</i> , With Similar Disease Severity to Wild Type, in <i>Helicobacter pylori</i> Infection of Symptomatic Lupus Fc γ R1I1b Deficient-Mice	13
<i>Helicobacter pylori</i> Infection Enhanced Anti-dsDNA Levels and Clinical Characteristics of Lupus in 24-Week-Old Fc γ R1I1b Deficient-mice	17
Enhanced Immune Cells in the Spleen of Fc γ R1I1b Deficient-Mice with <i>Helicobacter pylori</i> Infection	20
The Hyper-Responsiveness of Fc γ R1I1b $^{-/-}$ Macrophages to <i>Helicobacter pylori</i> Activation and the Loss of Response with Immune Complex Treatment	21
อภิปราย / วิจารณ์ (Discussion)	24
สรุปและเสนอแนะเกี่ยวกับการวิจัยในขั้นต่อไป ตลอดจนประโยชน์ในทางประยุกต์ของผลงานวิจัยที่ได้.....	26
ส่วนประกอบตอนท้าย.....	27
1. บรรณานุกรม (Bibliography).....	27
2. ภาคผนวก (Appendix) ถ้ามี	32
3. ประวัตินักวิจัยและคณะ พร้อมหน่วยงานสังกัด	32
4. ประวัติการศึกษา	33
5. สาขาวิชาการที่มีความชำนาญพิเศษ.....	33
โรคไตวายจากภาวะติดเชื้อในกระแสเลือด.....	33
6. ประสบการณ์ที่เกี่ยวข้องกับการบริหารงานวิจัยทั้งภายในและภายนอกประเทศ	33
7. ผู้อำนวยการแผนงานวิจัย : ชื่อแผนงานวิจัย -	33

สารบัญภาพ (List of Illustration)

Figure 1 Severity of <i>H. pylori</i> (HP) infection in symptomatic lupus (24-week-old) ($Fc\gamma RIIb^{-/-}$) and wild type ($Fc\gamma RIIb^{+/+}$) mice.....	14
Figure 2 Representative figures of urease test from gastric tissue of mice with <i>H. pylori</i> (HP) infection in the wild type ($Fc\gamma RIIb^{+/+}$) and lupus ($Fc\gamma RIIb^{-/-}$) mice.....	16
Figure 3 Severity of lupus in $Fc\gamma RIIb^{-/-}$ mice and wild type ($Fc\gamma RIIb^{+/+}$) with and without <i>H. pylori</i> (HP) infection	18
Figure 4 The Representative immunofluorescence images from glomeruli of wild type ($Fc\gamma RIIb^{+/+}$) with <i>H. pylori</i> (HP), $Fc\gamma RIIb^{-/-}$ mice with control phosphate buffer solution (PBS) gavage, and $Fc\gamma RIIb^{-/-}$ mice with <i>H. pylori</i> administration	19
Figure 5 Representative figures of renal histology of wild type ($Fc\gamma RIIb^{+/+}$) and $Fc\gamma RIIb^{-/-}$ mice with phosphate buffer solution (PBS) gavage (A,B) and <i>H. pylori</i> administration.....	20
Figure 6 Spleen demonstration	22
Figure 7 The representatives of flow-cytometric analysis	23
Figure 8 Phagocytosis and killing activity of macrophage from wild type ($Fc\gamma RIIb^{+/+}$) and $Fc\gamma RIIb^{-/-}$ mice in response against <i>H. pylori</i>	24

คำอธิบายสัญลักษณ์และคำย่อที่ใช้ในการวิจัย (LIST OF ABBREVIATIONS)

Fc γ RIIb: Fc gamma receptor IIb

PBS: Phosphate buffer solution

PCR: Polymerase chain reaction

FITC: Fluorescein isothiocyanate

BM: Bone marrow

MIP-2: Macrophage inflammatory protein-2

KC: Keratinocyte-derived cytokine

LPS: Lipopolysaccharide

BSA: Bovine serum albumin

MOI: Multiplicity of infection

PAS: Periodic acid-Schiff

H&E: Haematoxylin and eosin color

ส่วนประกอบเนื้อเรื่อง

บทนำ (Introduction)

Helicobacter pylori (HP), microaerophilic, spiral-shaped gram negative bacteria, are organisms that can survive in the highly acidic stomach environment, and are known to cause chronic gastric inflammation and cancer (Mahachai et al., 2016). The infection is very common among Asians, with a prevalence rate of up to 50–80% in some countries (Thirumurthi and Graham, 2012; Xie and Lu, 2015). Interestingly, eradication of HP in some patients with associated autoimmune diseases leads to long-term remission of the autoimmune disease (Fujimura et al., 2005; Kuwana, 2014). Moreover, HP infection down regulates the expression of Fc gamma receptor IIb (Fc γ RIIb), the only inhibitory Fc γ R (Bolland and Ravetch, 2000) on circulating monocyte of patients with autoimmune diseases (Asahi et al., 2008; Wu et al., 2012). As Fc γ receptors (Fc γ R) is the immunoglobulin superfamily that contributes to the protective functions, in part, by inducing phagocytosis of opsonized microbes, loss of the inhibitory Fc γ R results in effective organism control but enhances the risk of autoimmune diseases (Ravetch and Bolland, 2001). Although HP infection has shown a protective effect on the development of lupus in a case control study, especially among African-American patients, the relationship of lupus-HP is still intriguing (Sawalha et al., 2004; Hasni et al., 2011). Inadvertently, Fc γ RIIb dysfunction polymorphisms are common in Asia (Chu et al., 2004), partially due to the genetic pressure from malarial infection (Clatworthy et al., 2007). Although Fc γ RIIb dysfunction protects against malaria, the insufficient inhibitory signaling increases the risk of autoimmune activation. Indeed, the association between Fc γ RIIb polymorphisms and systemic lupus erythematosus (lupus) in patients has been reported (Tsuchiya and Kyogoku, 2005). Both Fc γ RIIb dysfunction polymorphisms and HP infection are common in the Asian population (Smith and Clatworthy, 2010; Hooi et al., 2017). While Fc γ RIIb loss-of-function is associated with lupus (Siriboonrit et al., 2003; Tsuchiya and Kyogoku, 2005; Jakes et al., 2012), HP infection has been associated with other autoimmune diseases such as immune thrombocytopenic purpura and membranous nephropathy (Hasni et al., 2011). As chronic inflammation accelerates lupus (Hasni et al., 2011) and the co-existence of Fc γ RIIb dysfunction polymorphisms with HP infection are possible, information on the responses of Fc γ RIIb^{-/-} mice to of HP infection in

patients with lupus. Thus this study tested HP infection in Fc γ RIIb^{-/-} condition, *in vivo* and *in vitro*.

เนื้อเรื่อง (Materials and Methods)

Animal and animal model

Fc γ RIIb^{-/-} mice on C57BL/6 background were kindly provided by Dr. Silvia Bolland (NIAID, NIH, Maryland, United States). Wild type female C57BL/6 mice were purchased from the National Laboratory Animal Center in Nakhon Pathom Province, Thailand. The animal protocols, as per NIH criteria, were approved by the Faculty of Medicine, Chulalongkorn University. Due to lupus manifestations' age-dependency, female symptomatic lupus (24-week-old with kidney injury) mice or age-matched wild-type control groups were used. Serum samples were collected through tail-vein nicking and through cardiac puncture at sacrifice for time-course analysis. Mice were sacrificed with cardiac puncture under isoflurane anesthesia and internal organs were collected, fixed in 10% formalin and embedded in paraffin. Staining in 4-mm sections with haematoxylin and eosin color (H&E) were used for further evaluation.

Helicobacter pylori Administration Model

HP ATCC 43504 (ATCC, Manassas, VA, United States) was cultured on supplemented Columbia agar (Oxoid, Hampshire, United Kingdom) under microaerophilic conditions (6–12% O₂, 5–8% CO₂) at 37°C for 48 h before use. The mouse model for HP infection was modified from a previous study (Konturek et al., 1999). Briefly, HP at 2 × 10⁹ CFU/ml in 0.5 ml phosphate buffer solution (PBS) control were orally administered twice daily for 2 weeks and once daily 3 weeks after. Mice were sacrificed at 1 week after the last administration of HP. Mouse blood was centrifuged and serum was kept at -80°C until analysis. Stomach was divided longitudinally through the greater and lesser curvature into several parts, washed with PBS, weighed and used to test HP burdens (i) by urease test, polymerase chain reaction (PCR) and direct culture, (ii), histopathology (fixed in 10% formaldehyde) and (iii) cytokine analysis from gastric tissue.

Urease Test, a Semi-Quantitative Analysis of Gastric *Helicobacter pylori* Burden

The principle of urease test is based on HP's urease enzyme production (Midolo and Marshall, 2000). Urease enzyme splits urea metabolites into ammonia and carbon dioxide, and ammonia alkalizes the culture media (the media color turns from yellow to pink). The stomach specimens (one-fourth of the total stomach tissue; 50 mg) were minced and directly put onto urea agar slant, and incubated at 37°C. The media color was observed at 24 h after incubation. As the color media alteration starts from the top to the bottom (Figure 3), the ratio of the pink color to the total depth of the media was used as a semi-quantitative measurement of HP burden.

Polymerase Chain Reaction (PCR), a Quantitative Analysis of Gastric *Helicobacter pylori* Burden

Quantitative real-time PCR of HP from gastric tissue were performed as previously described (He et al., 2002). In short, genomic DNA was extracted by High Pure PCR Template Preparation Kit (Roche, United States), and quantified by spectrophotometry (NanoDrop™, Thermo Fisher Scientific, United States). The primers of UREC gene-fragment were HPFOR (50-TTATCGGTAAAGACACCAGAAA -30) and HP-REV (50- ATCACAGCGCATGTCTTC -30). The amplification product was 132 bp and the genome size of HP ATCC 43504 (also designated HP CCUG 17874) was 1,615,763 bp (Clancy et al., 2012). Bacterial genome is approximately 1.06×10^9 g/mol and contains 6.02×10^{23} molecules/mol. One bacterium corresponds to 1.8 fg of DNA. The constructive of standard curve was created by the Light Cycler software using 10-fold serial dilution (3.6 fg-360 pg) per 5 ml of HP DNA, with bacterial concentrations ranging from of 2 to 2×10^5 bacteria. The profiling standard curve was indicated as a graph of crossing point (Cp) vs. bacterial number (CFUs). HP quantification was calculated by the standard curve and shown in bacterial number (CFUs).

Direct Culture, a Quantitative Analysis of Gastric *Helicobacter pylori* Burden

As an additional method, burdens of HP from gastric tissue were performed in a selective media (Skene et al., 2007). In brief, gastric samples were weighed, homogenized in 1 ml PBS and serially plated onto the supplemented Columbia agar (Oxoid, Hampshire, United Kingdom) with 10

mg/l vancomycin, 5 mg/l amphotericin B under microaerophilic conditions at 37°C for 48 h before bacterial enumeration.

Stomach Histology and Anti-*Helicobacter pylori* Antibody

Inflammatory response in stomach was scored by 2 blinded observers according to the Sydney Scoring System at 200 × magnification in 10 randomly selected fields of each sample (Dixon et al., 1996). The scoring system was determined by leukocyte mucosal infiltration with the following criteria; Score 0, normal; Score 1, mild; Score 2, moderate; Score 3 marked histopathological changes. In addition, serum anti-*H. pylori* IgG antibody (anti-HP) was measured by ELISA (My BioSource Inc, San Diego, CA, United States).

Cytokines Measurements in Gastric Tissues and Serum

Cytokine in gastric tissue was measured using the same method as in a previous publication (Ferrero et al., 2008). Briefly, gastric tissues were homogenized (Ultra-Turrax homogenizer, IKA, Staufen, Germany) in 500 ml of PBS containing protease inhibitor, centrifuged at 12,000 × g for 10 min at 4°C. The supernatant was collected and stored at -80°C until analyzed. Quantikine ELISA (ReproTech, NJ, United States) was used to measure CXC chemokines (MIP-2 and KC) and proinflammatory cytokines (IL-1b and TNF-a) in the supernatant and the serum.

Lupus Characteristics (Anti-dsDNA, Proteinuria, Serum Creatinine, and Renal Histology)

Lupus characteristics were analyzed as per the protocol in previous publication (Surawut et al., 2017). In brief, serum anti-dsDNA measurement was based on the ELISA assay of calf DNA (Invitrogen, Carlsbad, CA, United States) coated on 96-well plates (Surawut et al., 2017). Urine protein creatinine index (UPCI), a representative of 24 h proteinuria, was determined by the equation; spot urine protein/spot urine creatinine (Leelahavanichkul et al., 2010). Urine protein was measured by Bradford protein assay. Urine and serum creatinine levels were detected by QuantiChrom Creatinine Assay (DICT-500, BioAssay, and Hayward, CA, United States). For renal histology, kidneys were fixed in 10% formalin, paraffin embedded, and samples at 4 mm thickness were stained with Periodic acid-Schiff (PAS) reagent (Sigma-Aldrich) for the modified

semiquantitative assessment (Leelahavanichkul et al., 2010). Percentage of severe glomerular damage as determined by mesangial expansion > 60% of glomerular area or glomeruli with crescent formation was estimated at 400 × magnification to represent the severity of glomerular injury. Renal interstitial injury was estimated at 200 × magnification on 10 randomly selected fields for each kidney by the observation of the area of cellular infiltration in each field with the following semi-quantitative criteria: 0, area < 5%; 1, areas 5–15%; 2, area 15–30%; 3, area > 30–60%; 4, area > 60%. In addition, the immune complex deposition in renal tissue was detected by immunofluorescence following a standard protocol. In brief, the frozen section was fixed with acetone for 10 min and blocked with 1% bovine serum albumin (BSA) in PBS for 1 h at room temperature. The section was then stained with anti-Fc IgG for 1 h followed by IgG-Alexa-488 (secondary antibody). Then 300 nm of DAPI was added and incubated for 5 min in the dark.

An Analysis of Serum Gamma Globulin

For the evaluation of antibody responses, mouse serum was analyzed for total immunoglobulin by capillary protein electrophoresis (MINICAP-2 Sebia, Evry Cedex, France). The percentage of protein in the gamma zone of protein electrophoresis was converted into total immunoglobulin level by multiplying the ratio of protein at the gamma zone by serum total protein. Serum total protein and urine protein were measured by Bradford protein assay.

Flow Cytometry Analysis of Spleen

Flow cytometric analysis was performed following a standard protocol. In brief, spleens were minced in supplemented RPMI-1640 (Roswell Park Memorial Institute media), and the cells were centrifuged at 300 g for 5 min at 4°C. Red blood cells were removed using lysis buffer (ACK buffer: NH₄Cl, KHCO₃ and EDTA) and the splenocytes were washed twice in supplemented RPMI-1640. Subsequently, the splenocytes were resuspended in staining buffer (0.5% BSA and 10% FBS in PBS), and then were stained with fluorochrome-conjugated antibodies against different mouse immune cells including; CD19, CD80, CD138, CD3, CD4, CXCR5, B220, CD19, GL-7 and F4/80 (BioLegend). All stained cells were analysed by flow cytometer using BD LSR-II (BD Biosciences) and data analysis by FlowJo software (version 10).

Macrophages Phagocytosis and Macrophage Killing Activity

Macrophages were derived from the bone marrow (BM) (Ondee et al., 2017) and phagocytosis assay was performed following an established protocol (Chmiela et al., 1997; Miliukene et al., 2007). In short, 1×10^9 cell/ml heat-killed HP (60°C for 30 min) was incubated with 100 mg/ml fluorescein isothiocyanate (FITC) (Sigma, United States) in PBS at 35°C for 30 min for FITC labeling. This was then mixed with activated macrophages at multiplicity of infection (MOI) 500:1 (HP-FITC: macrophage) in DMEM complete media with 5% mouse normal serum (as opsonin) in 96-well polystyrene tissue culture plates. Of note, the high MOI was necessary for the adequate fluorescent intensity for the detection of phagocytosis activity. The incubation with 10 ng/ml IFN- γ (Biolegend, United States) for 17 h followed by 100 ng/ml of lipopolysaccharide (LPS; Sigma, United States) for 24 h was performed for macrophage activation. Supernatant IL-12p70 was measured by ELISA (eBioscience, United States) to support the activated-state of macrophage.

Macrophages and HP were allowed for phagocytosis for 0.5, 1, and 2 h. At each time point, all media was removed and 100 μ l/well of 0.2% trypan blue in PBS was added to quench extracellular FITC labeled-bacteria. Phagocytosis activity was determined by the detection of intracellular bacteria with fluorescent intensity read at 492 nm excitation and 518 nm emission wavelengths. On the other hand, the killing assay was performed as previously published (Keep et al., 2010). In brief, live HP to macrophage at MOI 500:1, as described above, was allowed for phagocytosis for 0.5 h. Then, the media and extracellular bacteria were removed, 100 mg/ml gentamycin was added for 1 h at 37°C, 5% CO₂ to eliminate the remaining extracellular bacteria. Cells were washed with PBS 5 times, the final wash was plated in Columbia agar (Oxoid, United Kingdom) to ensure that no extracellular bacteria remained after washing. Then the remaining HP-phagocytized cells were used to determine the intracellular bacteria at 0.5 h phagocytosis, while some of the wells with HP-phagocytized cells were further incubated for 2 and 6 h after extracellular bacteria removal process before bacterial determination. For intracellular bacterial determination, 200 μ l/well of 0.1% saponin was added for 15 min at 37°C, 5% CO₂ to release intracellular bacteria, serially diluted and plated on Columbia agar (Oxoid, United Kingdom) incubated under microaerophilic conditions at 37°C up to 5 days for colony enumeration. The macrophage killing

activity was determined by intracellular proliferation rate at each time-point by the ratio of colony forming unit (CFU) of bacteria at the specific time-point divided by CFU at 0.5 h phagocytosis.

Since immune complex (IC) can affect phagocytosis and killing activity of macrophage, the functions with and without IC treated conditions were tests. The ICs were generated as described previously (Ding et al., 2015). Briefly, mouse IgG1 anti-ovalbumin (anti-OVA; Sigma-Aldrich) was mixed with ovalbumin (OVA; Sigma-Aldrich) followed by incubation at room temperature for 30 min to allow IC formation. Then the ICs were challenged with macrophages for 24 h before performing phagocytosis and killing assay. Macrophages without ICs activation was used as a control condition. In addition, to test if serum of symptomatic Fc γ RIIb $^{-/-}$ mice influenced macrophage functions, 10% mouse serum (in DMEM) from Fc γ RIIb $^{-/-}$ (symptomatic lupus) or wild type (control) was incubated with macrophage for 24 h before performing phagocytosis and killing activity assay.

Statistical Analysis

Mean \pm standard error (SE) was used for data presentation. Unpaired Student's t-test or one-way analysis of variance (ANOVA) with Tukey's comparison test was used for the analysis of experiments with groups 2 and 3, respectively, the repeated measures ANOVA with Bonferroni post hoc analysis was used for the analysis of data with several time-points. P-values < 0.05 were considered statistically significant. SPSS 11.5 software (SPSS Inc., Chicago, IL, United States) was used for all statistical analysis.

Result (ผลการทดลอง)

The Prominent Anti-*Helicobacter pylori*, With Similar Disease Severity to Wild Type, in *Helicobacter pylori* Infection of Symptomatic Lupus Fc γ RIIb Deficient-Mice

Characteristics as determined by serum creatinine proteinuria, and anti-dsDNA in Fc γ RIIb $^{-/-}$ mice after 24-week-old is previously described (Ondee et al., 2017; Surawut et al., 2017). Hence, HP administration in 24-week-old mice represents HP infection in patients with symptomatic lupus. Indeed, HP infection caused significant weight loss in both wild type and Fc γ RIIb $^{-/-}$ mice (Figures 1A,B) and the wild type demonstrated a little bit more prominent weight

loss. In addition, similar disease severity between both strains were demonstrated with (i) bacterial burdens in stomach with semi-quantitative assay (urease test) (Figures 1C, 2A) and quantitative methods (real-time PCR and direct culture from stomach tissue) (Figures 1D,E), (ii) histological inflammation in stomach (Figures 1F, 2B–D) and (iii) macrophage inflammatory protein-2 (MIP-2) and keratinocyte-derived cytokine (KC), the important chemokine of HP pathogenesis (Sgouras et al., 2005; De Filippo et al., 2008), in gastric-tissue (Figures 1G,H). Despite the similar severity of HP infection between both strains, $Fc\gamma RIIb^{-/-}$ mice had the higher serum anti-HP IgG than wild type (Figure 1I).




Figure 1 Severity of *H. pylori* (HP) infection in symptomatic lupus (24-week-old) ($Fc\gamma RIIb^{-/-}$) and wild type ($Fc\gamma RIIb^{+/+}$) mice

Severity of *H. pylori* (HP) infection in symptomatic lupus (24-week-old) ($Fc\gamma RIIb^{-/-}$) and wild type ($Fc\gamma RIIb^{+/+}$) mice as determined by body weight (A), body weight alteration (B), stomach bacterial burdens by the

*semi-quantitative scoring of urease test, polymerase chain reaction (PCR) and the direct culture on selective media (direct culture) (C-E), gastric inflammatory score (F), gastric cytokines (MIP-2 and KC) (G,H), and serum anti-HP IgG antibody (I) (n = 5-7/group) were demonstrated. MIP-2; Macrophage Inflammatory Protein-2, KC; Keratinocyte Chemoattractant; *p < 0.05.*




Figure 2 Representative figures of urease test from gastric tissue of mice with *H. pylori* (HP) infection in the wild type ($Fc\gamma RIIb^{+/+}$) and lupus ($Fc\gamma RIIb^{-/-}$) mice

Representative figures of urease test from gastric tissue of mice with *H. pylori* (HP) infection in the wild type ($Fc\gamma RIIb^{+/+}$) and lupus ($Fc\gamma RIIb^{-/-}$) mice (A) were demonstrated. Gastric histopathology in wild type and $Fc\gamma RIIb^{-/-}$ mice with HP infection (B,C) and wild-type with phosphate buffer solution (PBS) gavage (D) are

shown. (Of note, gastric histology of *FcγRIIb*^{-/-} mice with PBS was not demonstrated due to the non-difference from wild type with PBS.)

***Helicobacter pylori* Infection Enhanced Anti-dsDNA Levels and Clinical Characteristics of Lupus in 24-Week-Old *FcγRIIb* Deficient-mice**

HP infection has been shown to enhance auto-antibodies (Yamanishi et al., 2006; Hasni et al., 2011), thus this study specifically looked at anti-dsDNA levels, a specific auto-antibody of lupus, which also helps determine disease severity. Indeed, HP induced anti-dsDNA in wild-types and accelerated anti-dsDNA level in *FcγRIIb*^{-/-} (Figure 3A). Although HP induced anti-dsDNA in both mouse strains, anti-dsDNA levels were more prominent in *FcγRIIb*^{-/-} group (Figure 3A), implying the autoimmune inducibility of *FcγRIIb*^{-/-} mice. As most of the serum protein in gamma zone of serum protein electrophoresis analysis is immunoglobulin, serum gamma globulin is measured as a representative of total immunoglobulin. Interestingly, HP infection enhanced immunoglobulin production in both strains but more predominantly in *FcγRIIb*^{-/-} mice (Figure 3B and Supplementary Figure S1). This is in concordance with the higher level of serum anti-HP and anti-dsDNA in *FcγRIIb*^{-/-} mice (Figures 1I, 3A). In addition, there was prominent immunoglobulin deposition in the glomeruli of *FcγRIIb*^{-/-} mice (Figure 4) with the enhanced severity of lupus nephritis as demonstrated with serum creatinine, urine protein (urine protein creatinine index; UPCI), renal histology and serum cytokines (IL-6, MIP-2 and KC; the representatives of systemic inflammatory responses) (Figures 3C–H, 5). HP induced chemokine responses both locally (gastric tissue) (Figures 1H,I) and systemically (Figures 3H,I). With HP infection, gastric cytokines were not different between wild type and *FcγRIIb*^{-/-} mice but serum cytokines were more prominent in the *FcγRIIb*^{-/-} group.




Figure 3 Severity of lupus in Fc γ RIIb $^{-/-}$ mice and wild type (Fc γ RIIb +/+) with and without *H. pylori* (HP) infection

Severity of lupus in Fc γ RIIb $^{-/-}$ mice and wild type (Fc γ RIIb +/+) with and without *H. pylori* (HP) infection as determined by anti-dsDNA (A); serum gammaglobulin (B); serum creatinine (C); urine protein creatinine index (UPCI) (D); renal injury score of glomerular and tubular lesion (E,F); and serum cytokines (IL-6, MIP-2 and KC) (G-I) were demonstrated ($n = 5-7/$ time-point and $5-7/group$). MIP-2; Macrophage Inflammatory Protein-2, KC; Keratinocyte Chemoattractant; * $p < 0.05$.




Figure 4 The Representative immunofluorescence images from glomeruli of wild type (Fc γ R1Ib +/+) with *H. pylori* (HP), Fc γ R1Ib^{-/-} mice with control phosphate buffer solution (PBS) gavage, and Fc γ R1Ib^{-/-} mice with *H. pylori* administration

The Representative immunofluorescence images from glomeruli of wild type (Fc γ R1Ib +/+) with *H. pylori* (HP) (A–C), Fc γ R1Ib^{-/-} mice with control phosphate buffer solution (PBS) gavage (D–F), and Fc γ R1Ib^{-/-} mice with *H. pylori* administration (G–I) were demonstrated. Original magnification 600 \times ; goat anti-mouse IgG with Fluorescein isothiocyanate (FITC) (green) and DAPI (blue) were used for the identification of Fc portion of the immune complex deposition and nucleus, respectively. (Of note, the glomerulus of wild-type mice with PBS was not demonstrated due to the non-difference from wild type with HP.)




Figure 5 Representative figures of renal histology of wild type ($Fc\gamma RIIb^{+/+}$) and $Fc\gamma RIIb^{-/-}$ mice with phosphate buffer solution (PBS) gavage (A,B) and *H. pylori* administration

Representative figures of renal histology of wild type ($Fc\gamma RIIb^{+/+}$) and $Fc\gamma RIIb^{-/-}$ mice with phosphate buffer solution (PBS) gavage (A,B) and *H. pylori* administration (C,D) were demonstrated. Original magnification 400 \times .

Enhanced Immune Cells in the Spleen of $Fc\gamma RIIb$ Deficient-Mice with *Helicobacter pylori* Infection

Due to the prominent immunoglobulin production in $Fc\gamma RIIb^{-/-}$ mice with HP infection, lymphoid organs in these mice were examined. It is surprising that there was non-difference in gastric weight and mucosal associated lymphoid tissue morphology between wild type and $Fc\gamma RIIb^{-/-}$ mice with or without HP infection (data not shown). Spleen weight among these mice was different. Spleen weight without HP infection of $Fc\gamma RIIb^{-/-}$ mice was higher than wild type and the infection enhanced $Fc\gamma RIIb^{-/-}$ spleen weight but not wild type spleen (Figure 6A). Thus, we examined splenocyte by flow cytometry analysis (Figures 6B–G, 7). Without HP, plasma cell

(CD138⁺) was the only cell population that was different between wild type and Fc γ RIIb^{-/-} mice (Figure 6B). In Fc γ RIIb^{-/-} mice with HP infection, there was an increase in plasma cells, activated B cells (CD19⁺ and CD80⁺) and follicular helper T cells (CD3⁺, CD4⁺ and CXCR5⁺) but not follicular B cells (CXCR5⁺ and B220⁺), germinal center B cells (CD19⁺ and GC⁺) and macrophages (F4/80⁺) in comparison with Fc γ RIIb^{-/-} without HP or wild type with HP (Figures 6B–G). Only follicular helper T cells were increased in wild type with HP compared to wild type without HP infection (Figure 6F). This data supports the hyper-immune response of Fc γ RIIb^{-/-} against HP compared with wild type.

The Hyper-Responsiveness of Fc γ RIIb^{-/-} Macrophages to *Helicobacter pylori* Activation and the Loss of Response with Immune Complex Treatment

We examined macrophage functions, *in vitro*, as a pilot experiment because (i) the influence of macrophage against HP in lupus and wild type might be different, (ii) the possible effect of high circulating immune complex against macrophage functions (Bolland and Ravetch, 2000; Clatworthy et al., 2007; Surawut et al., 2017) and (iii) the lack of data on Fc γ RIIb^{-/-} macrophage against HP. Interestingly, Fc γ RIIb^{-/-} macrophage showed more prominent phagocytosis than wild type after 0.5 h of incubation, however, this was not the case after 1 or 2 h of incubation (Figures 8A,C). In addition, the IC incubation reduced phagocytosis at 0.5 h in both groups of macrophage and at 1 h in Fc γ RIIb^{-/-} group (Figure 8A). Further, Fc γ RIIb^{-/-} macrophage showed prominent killing activity over wild type at both time-points (lower intracellular bacteria) (Figures 8B, D). After IC-incubation, the killing activity worsened in both strains of macrophage, but predominantly in the wild type cells (Figure 8B). Interestingly, pre-treatment macrophage with serum from Fc γ RIIb^{-/-} mice, but not wild type serum, reduced macrophage killing activity without the influence on phagocytosis activity (Figures 8C, D). This implies that there are some macrophage-neutralizing factors in serum of symptomatic lupus mice.




Figure 6 Spleen demonstration

Spleen weight ($n = 5/\text{group}$) (A) and the quantitative flow-cytometric analysis of splenocytes from wild type (Fc γ RIIb^{+/+}) and Fc γ RIIb^{-/-} mice with phosphate buffer solution (PBS) gavage or *H. pylori* administration in the spleen plasma cell (CD138⁺) (B), spleen activated B cell (CD19⁺ and CD80⁺) (C), spleen germinal center B cell (CD19⁺ GC⁺) (D), spleen follicular B cell (CXCR5⁺ and B220⁺) (E), spleen follicular helper T cell (CD3⁺ and CD4⁺ and CXCR5⁺) (F) and spleen macrophage (F4/80⁺) (G) were demonstrated. ($n = 5-8/\text{group}$); * $p < 0.05$




Figure 7 The representatives of flow-cytometric analysis

The representatives of flow-cytometric analysis were demonstrated; spleen plasma cell (A) and spleen follicular helper T cell (B).




Figure 8 Phagocytosis and killing activity of macrophage from wild type ($Fc\gamma RIIB^{+/+}$) and $Fc\gamma RIIB^{-/-}$ mice in response against *H. pylori*

Phagocytosis and killing activity of macrophage from wild type ($Fc\gamma RIIB^{+/+}$) and $Fc\gamma RIIB^{-/-}$ mice in response against *H. pylori* and these functions after incubation with immune complex incubation (A, B) or mouse serum from wild type and $Fc\gamma RIIB^{-/-}$ mice (C, D) were demonstrated (experiments were performed in triplicate). * $p < 0.05$; # $p < 0.05$ vs. untreated or treated with serum from $Fc\gamma RIIB^{-/-}$ mice.

อภิปราย / วิจารณ์ (Discussion)

Although a previous case-control study demonstrates low prevalence of HP infection in patients with lupus (Sawalha et al., 2004), there has been no other studies exploring the lupus-HP relationship. Despite the case-control study in that report, it is still unclear if the immune response of

patients with lupus prone genes is effective against HP or HP infection is protective for lupus. Hence, we explored lupus-HP relationship in $Fc\gamma RIIb^{-/-}$ lupus mice in this study.

There was enhanced antibody production and lupus acceleration in $Fc\gamma RIIb^{-/-}$ mice with HP gastritis, a localized infection. There was not only the increase in anti-HP, a specific antibody against HP, but also anti-dsDNA and serum gamma immunoglobulin in $Fc\gamma RIIb^{-/-}$ mice with HP. Interestingly, it seems that the spleen, but not the gastric lymphoid tissue, was responsible for the prominent antibody production in $Fc\gamma RIIb^{-/-}$ with HP because of the increased weight of the spleen, not the stomach. HP infection induced several immune cells that associated with the antibody production process in the spleen, including activated B cell, plasma cell and follicular helper T-cell. In the wild type with HP, anti-HP increased without spleen activation and serum immunoglobulin. Indeed, HP infection activated only gastric lymphoid organ and lymphocyte but not the spleen in the wild type mice (Bussiere et al., 2006; Floch et al., 2015). The systemic response against HP (serum cytokines) was found only in $Fc\gamma RIIb^{-/-}$ mice but not wild type supporting the hyper-inflammatory responses of $Fc\gamma RIIb^{-/-}$ mice. It is interesting to note that increased serum cytokines after HP infection is demonstrated in most of the studies on mouse model (Kodama et al., 2005) and juvenile patients (Khaiboullina et al., 2016) but not in other group of patients (Bayraktaroglu et al., 2004). Although there is no data on the influence of increased systemic cytokines in patients with HP, our study implicated the importance of increased systemic cytokines in lupus with HP infection.

It is well known that chronic infection and inflammation initiates and accelerates lupus (Munoz et al., 2010; Esposito et al., 2014; Podolska et al., 2015; Rigante and Esposito, 2015) and the hyper-inflammatory responses in $Fc\gamma RIIb^{-/-}$ mice due to the inhibitory signaling defect (Clatworthy et al., 2007) might enhance this effect. Thus, increased antibody production in $Fc\gamma RIIb^{-/-}$ mice with HP might be due to the prominent systemic responses against HP infection. Perhaps, the persistent gastric inflammation from HP infection induces epitope spreading and/or bystander activation in $Fc\gamma RIIb^{-/-}$ mice resulting in the increased auto-antibody. As such, HP enhanced anti-dsDNA levels in both strains, but more predominantly in $Fc\gamma RIIb^{-/-}$, supports the

well-known HP-induced autoimmunity hypothesis (Hasni et al., 2011). In addition, the increased anti-dsDNA in Fc γ RIIb^{-/-} mice also enhanced lupus severity, supporting its role in lupus pathogenesis (Giles and Boackle, 2013)

Regarding the increased anti-HP antibody (**Figure 1I**) and the prominent macrophage functions (Bolland and Ravetch, 2000; Clatworthy et al., 2007; Surawut et al., 2017) in Fc γ RIIb^{-/-} mice, the lower bacterial burdens and the more severe gastritis were expected in these mice compared with wild type. This is due to the attenuation property of anti-HP and the macrophage enhanced gastritis in macrophage depleted wild type mice (Kaparakis et al., 2008). Surprisingly, bacterial burdens and gastritis severity were not different between the 2 groups. This suggests different influence of immune responses or different neutralizing factor of antibody between wild type and lupus mice. Moreover, infection susceptibility and high circulating immune complex (CIC) in symptomatic lupus is well-known, thus the negative influence of CIC in lupus against infection is possible. Indeed, we demonstrated the inhibitory effect of IC and lupus mouse serum against macrophage phagocytosis and killing activity, in vitro, in both wild type and Fc γ RIIb^{-/-} macrophage which, at least in part, explained the infection susceptibility of lupus. Despite several macrophage-neutralizing factors (e.g., uremic toxins) in Fc γ RIIb^{-/-} mouse serum, CIC might contribute some influences. More studies on this subject are necessary.

Several limitations of translation research should be considered before applying any clinical translation such as; (i) mouse is not the natural host of HP and repeated gavage of HP is different from the disease's natural course, (ii) there are some different properties and expressions of Fc γ RIIb receptor between human and mouse (Bruhns, 2012; Hussain et al., 2015), (iii) unmeasured factors might also affect the model due to other Fc γ RIIb^{-/-} characteristics, and (iv) the opsonin used for macrophage activity assays, in vitro, might not resemble the in vivo physiology.

สรุปและเสนอแนะเกี่ยวกับการวิจัยในขั้นต่อไป ตลอดจนประโยชน์ในทางประยุกต์ของผลงานวิจัยที่ได้

Prominence of anti-HP, anti-dsDNA and increased serum immunoglobulin despite the similar disease severity of HP infection in Fc γ RIIb^{-/-} mice compared with wild type were

demonstrated. HP infection in Fc γ RIIb^{-/-} mice enhanced systemic inflammation, induced antibody-producing immune cells in the spleen and enhanced lupus disease severity. Thus, the localized HP gastritis may induce the systemic inflammatory responses and enhance lupus progression in some patients with lupus. Thus patients with dyspepsia or increased systemic cytokine of unknown causes should be further investigated for HP-induced chronic gastritis. Clinical studies to confirm these findings in humans are necessary, which may change our current approach to clinical management of lupus.

ส่วนประกอบตอนท้าย

1. บรรณานุกรม (Bibliography)

1. Mahachai V, Vilaichone RK, Pittayanon R, Rojborwonwitaya J, Leelakusolvong S, Kositchaiwat C, et al. Thailand Consensus on Helicobacter pylori Treatment 2015. *Asian Pac J Cancer Prev*. 2016;17(5):2351-60. PubMed PMID: 27268597.
2. Xie C, Lu NH. Review: clinical management of Helicobacter pylori infection in China. *Helicobacter*. 2015;20(1):1-10. doi: 10.1111/hel.12178. PubMed PMID: 25382801.
3. Thirumurthi S, Graham DY. Helicobacter pylori infection in India from a western perspective. *Indian J Med Res*. 2012;136(4):549-62. PubMed PMID: 23168695; PubMed Central PMCID: PMC3516022.
4. Kuwana M. Helicobacter pylori-associated immune thrombocytopenia: clinical features and pathogenic mechanisms. *World J Gastroenterol*. 2014;20(3):714-23. doi: 10.3748/wjg.v20.i3.714. PubMed PMID: 24574745; PubMed Central PMCID: PMC3921481.
5. Fujimura K, Kuwana M, Kurata Y, Imamura M, Harada H, Sakamaki H, et al. Is eradication therapy useful as the first line of treatment in Helicobacter pylori-positive idiopathic thrombocytopenic purpura? Analysis of 207 eradicated chronic ITP cases in Japan. *Int J Hematol*. 2005;81(2):162-8. PubMed PMID: 15765787.
6. Bolland S, Ravetch JV. Spontaneous autoimmune disease in Fc(gamma)RIIB-deficient mice results from strain-specific epistasis. *Immunity*. 2000;13(2):277-85. PubMed PMID: 10981970.

7. Asahi A, Nishimoto T, Okazaki Y, Suzuki H, Masaoka T, Kawakami Y, et al. Helicobacter pylori eradication shifts monocyte Fcγ receptor balance toward inhibitory FcγRIIB in immune thrombocytopenic purpura patients. *J Clin Invest*. 2008;118(8):2939-49. doi: 10.1172/JCI34496. PubMed PMID: 18654664; PubMed Central PMCID: PMCPMC2483681.
8. Wu Z, Zhou J, Prsoon P, Wei X, Liu X, Peng B. Low expression of FCGR1B in macrophages of immune thrombocytopenia-affected individuals. *Int J Hematol*. 2012;96(5):588-93. doi: 10.1007/s12185-012-1187-6. PubMed PMID: 23054650.
9. Ravetch JV, Bolland S. IgG Fc receptors. *Annu Rev Immunol*. 2001;19:275-90. doi: 10.1146/annurev.immunol.19.1.275. PubMed PMID: 11244038.
10. Sawalha AH, Schmid WR, Binder SR, Bacino DK, Harley JB. Association between systemic lupus erythematosus and Helicobacter pylori seronegativity. *J Rheumatol*. 2004;31(8):1546-50. PubMed PMID: 15290733.
11. Hasni S, Ippolito A, Illei GG. Helicobacter pylori and autoimmune diseases. *Oral Dis*. 2011;17(7):621-7. doi: 10.1111/j.1601-0825.2011.01796.x. PubMed PMID: 21902767; PubMed Central PMCID: PMCPMC3653166.
12. Chu ZT, Tsuchiya N, Kyogoku C, Ohashi J, Qian YP, Xu SB, et al. Association of Fcγ receptor 1b polymorphism with susceptibility to systemic lupus erythematosus in Chinese: a common susceptibility gene in the Asian populations. *Tissue Antigens*. 2004;63(1):21-7. PubMed PMID: 14651519.
13. Clatworthy MR, Willcocks L, Urban B, Langhorne J, Williams TN, Peshu N, et al. Systemic lupus erythematosus-associated defects in the inhibitory receptor FcγRIIb reduce susceptibility to malaria. *Proc Natl Acad Sci U S A*. 2007;104(17):7169-74. doi: 10.1073/pnas.0608889104. PubMed PMID: 17435165; PubMed Central PMCID: PMCPMC1855357.
14. Tsuchiya N, Kyogoku C. Role of Fc γ receptor 1b polymorphism in the genetic background of systemic lupus erythematosus: insights from Asia. *Autoimmunity*. 2005;38(5):347-52. doi: 10.1080/08916930500123926. PubMed PMID: 16227149.
15. Hooi JKY, Lai WY, Ng WK, Suen MMY, Underwood FE, Tanyingoh D, et al. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. *Gastroenterology*. 2017;153(2):420-9. doi: 10.1053/j.gastro.2017.04.022. PubMed PMID: 28456631.

16. Smith KG, Clatworthy MR. FcγRIIB in autoimmunity and infection: evolutionary and therapeutic implications. *Nat Rev Immunol*. 2010;10(5):328-43. doi: 10.1038/nri2762. PubMed PMID: 20414206; PubMed Central PMCID: PMC4148599.
17. Jakes RW, Bae SC, Louthrenoo W, Mok CC, Navarra SV, Kwon N. Systematic review of the epidemiology of systemic lupus erythematosus in the Asia-Pacific region: prevalence, incidence, clinical features, and mortality. *Arthritis Care Res (Hoboken)*. 2012;64(2):159-68. doi: 10.1002/acr.20683. PubMed PMID: 22052624.
18. Siriboonrit U, Tsuchiya N, Sirikong M, Kyogoku C, Bejrachandra S, Suthipinittharm P, et al. Association of Fcγ receptor IIb and IIIb polymorphisms with susceptibility to systemic lupus erythematosus in Thais. *Tissue Antigens*. 2003;61(5):374-83. PubMed PMID: 12753656.
19. Konturek PC, Brzozowski T, Konturek SJ, Stachura J, Karczewska E, Pajdo R, et al. Mouse model of *Helicobacter pylori* infection: studies of gastric function and ulcer healing. *Aliment Pharmacol Ther*. 1999;13(3):333-46. PubMed PMID: 10102967.
20. Midolo P, Marshall BJ. Accurate diagnosis of *Helicobacter pylori*. Urease tests. *Gastroenterol Clin North Am*. 2000;29(4):871-8. PubMed PMID: 11190071.
21. He Q, Wang JP, Osato M, Lachman LB. Real-time quantitative PCR for detection of *Helicobacter pylori*. *J Clin Microbiol*. 2002;40(10):3720-8. PubMed PMID: 12354871; PubMed Central PMCID: PMC130860.
22. Clancy CD, Forde BM, Moore SA, O'Toole PW. Draft genome sequences of *Helicobacter pylori* strains 17874 and P79. *J Bacteriol*. 2012;194(9):2402. doi: 10.1128/JB.00230-12. PubMed PMID: 22493206; PubMed Central PMCID: PMC3347063.
23. Skene C, Young A, Every A, Sutton P. *Helicobacter pylori* flagella: antigenic profile and protective immunity. *FEMS Immunol Med Microbiol*. 2007;50(2):249-56. doi: 10.1111/j.1574-695X.2007.00263.x. PubMed PMID: 17521391.
24. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. *Am J Surg Pathol*. 1996;20(10):1161-81. PubMed PMID: 8827022.

25. Ferrero RL, Ave P, Ndiaye D, Bambou JC, Huerre MR, Philpott DJ, et al. NF-kappaB activation during acute *Helicobacter pylori* infection in mice. *Infect Immun*. 2008;76(2):551-61. doi: 10.1128/IAI.01107-07. PubMed PMID: 18070899; PubMed Central PMCID: PMCPMC2223451.
26. Surawut S, Ondee T, Taratummarat S, Palaga T, Pisitkun P, Chindamporn A, et al. The role of macrophages in the susceptibility of Fc gamma receptor IIb deficient mice to *Cryptococcus neoformans*. *Sci Rep*. 2017;7:40006. doi: 10.1038/srep40006. PubMed PMID: 28074867; PubMed Central PMCID: PMCPMC5225418.
27. Leelahavanichkul A, Yan Q, Hu X, Eisner C, Huang Y, Chen R, et al. Angiotensin II overcomes strain-dependent resistance of rapid CKD progression in a new remnant kidney mouse model. *Kidney Int*. 2010;78(11):1136-53. doi: 10.1038/ki.2010.287. PubMed PMID: 20736988; PubMed Central PMCID: PMCPMC3113489.
28. Ondee T, Surawut S, Taratummarat S, Hirankarn N, Palaga T, Pisitkun P, et al. Fc Gamma Receptor IIB Deficient Mice: A Lupus Model with Increased Endotoxin Tolerance-Related Sepsis Susceptibility. *Shock*. 2017;47(6):743-52. doi: 10.1097/SHK.0000000000000796. PubMed PMID: 27849678.
29. Chmiela M, Czkwianianc E, Wadstrom T, Rudnicka W. Role of *Helicobacter pylori* surface structures in bacterial interaction with macrophages. *Gut*. 1997;40(1):20-4. PubMed PMID: 9155570; PubMed Central PMCID: PMCPMC1027002.
30. Miliukene VV, Biziuliavichene G, Khaustova LP, Pilinkene AV, Biziuliavichius GA. [Determination of quantitative parameters of *Escherichia coli* phagocytosis by mouse peritoneal macrophages]. *Tsitologija*. 2007;49(10):853-7. PubMed PMID: 18074775.
31. Keep S, Borlace G, Butler R, Brooks D. Role of immune serum in the killing of *Helicobacter pylori* by macrophages. *Helicobacter*. 2010;15(3):177-83. doi: 10.1111/j.1523-5378.2010.00750.x. PubMed PMID: 20557358.
32. Ding J, Fang Y, Xiang Z. Antigen/IgG immune complex-primed mucosal mast cells mediate antigen-specific activation of co-cultured T cells. *Immunology*. 2015;144(3):387-94. doi: 10.1111/imm.12379. PubMed PMID: 25196548; PubMed Central PMCID: PMCPMC4557675.
33. Sgouras DN, Panayotopoulou EG, Martinez-Gonzalez B, Petraki K, Michopoulos S, Mentis A. *Lactobacillus johnsonii* La1 attenuates *Helicobacter pylori*-associated gastritis and reduces

levels of proinflammatory chemokines in C57BL/6 mice. *Clin Diagn Lab Immunol*. 2005;12(12):1378-86. doi: 10.1128/CDLI.12.12.1378-1386.2005. PubMed PMID: 16339060; PubMed Central PMCID: PMCPMC1317072.

34. De Filippo K, Henderson RB, Laschinger M, Hogg N. Neutrophil chemokines KC and macrophage-inflammatory protein-2 are newly synthesized by tissue macrophages using distinct TLR signaling pathways. *J Immunol*. 2008;180(6):4308-15. PubMed PMID: 18322244.

35. Yamanishi S, Iizumi T, Watanabe E, Shimizu M, Kamiya S, Nagata K, et al. Implications for induction of autoimmunity via activation of B-1 cells by *Helicobacter pylori* urease. *Infect Immun*. 2006;74(1):248-56. doi: 10.1128/IAI.74.1.248-256.2006. PubMed PMID: 16368978; PubMed Central PMCID: PMCPMC1346662.

36. Kaparakis M, Walduck AK, Price JD, Pedersen JS, van Rooijen N, Pearce MJ, et al. Macrophages are mediators of gastritis in acute *Helicobacter pylori* infection in C57BL/6 mice. *Infect Immun*. 2008;76(5):2235-9. doi: 10.1128/IAI.01481-07. PubMed PMID: 18332213; PubMed Central PMCID: PMCPMC2346689.

37. Bussiere FI, Chaturvedi R, Asim M, Hoek KL, Cheng Y, Gainor J, et al. Low multiplicity of infection of *Helicobacter pylori* suppresses apoptosis of B lymphocytes. *Cancer Res*. 2006;66(13):6834-42. doi: 10.1158/0008-5472.CAN-05-4197. PubMed PMID: 16818661.

38. Floch P, Laur AM, Korolik V, Chriment D, Cappellen D, Idrissi Y, et al. Characterisation of inflammatory processes in *Helicobacter pylori*-induced gastric lymphomagenesis in a mouse model. *Oncotarget*. 2015;6(33):34525-36. doi: 10.18632/oncotarget.5948. PubMed PMID: 26439692; PubMed Central PMCID: PMCPMC4741470.

39. Kodama M, Murakami K, Sato R, Okimoto T, Nishizono A, Fujioka T. *Helicobacter pylori*-infected animal models are extremely suitable for the investigation of gastric carcinogenesis. *World J Gastroenterol*. 2005;11(45):7063-71. PubMed PMID: 16437649; PubMed Central PMCID: PMCPMC4725077.

40. Khaiboullina SF, Abdulkhakov S, Khalikova A, Safina D, Martynova EV, Davidyuk Y, et al. Serum Cytokine Signature That Discriminates *Helicobacter pylori* Positive and Negative Juvenile Gastroduodenitis. *Front Microbiol*. 2016;7:1916. doi: 10.3389/fmicb.2016.01916. PubMed PMID: 28018296; PubMed Central PMCID: PMCPMC5156714.

41. Taner Bayraktaroğlu AŞA, Selim Aydemir, Can Davutoğlu, Yücel Üstündağ, Hulusi Atmaca, and Ali Borazan. Serum levels of tumor necrosis factor- α , interleukin-6 and interleukin-8 are not increased in dyspeptic patients with Helicobacter pylori-associated gastritis. *Mediators of Inflammation*. 2004;13(1):25-8.
42. Munoz LE, Janko C, Schulze C, Schorn C, Sarter K, Schett G, et al. Autoimmunity and chronic inflammation - two clearance-related steps in the etiopathogenesis of SLE. *Autoimmun Rev*. 2010;10(1):38-42. doi: 10.1016/j.autrev.2010.08.015. PubMed PMID: 20817127.
43. Podolska MJ, Biermann MH, Maueroeder C, Hahn J, Herrmann M. Inflammatory etiopathogenesis of systemic lupus erythematosus: an update. *J Inflamm Res*. 2015;8:161-71. doi: 10.2147/JIR.S70325. PubMed PMID: 26316795; PubMed Central PMCID: PMC4548750.
44. Rigante D, Esposito S. Infections and Systemic Lupus Erythematosus: Binding or Sparring Partners? *Int J Mol Sci*. 2015;16(8):17331-43. doi: 10.3390/ijms160817331. PubMed PMID: 26230690; PubMed Central PMCID: PMC4581196.
45. Esposito S, Bosis S, Semino M, Rigante D. Infections and systemic lupus erythematosus. *Eur J Clin Microbiol Infect Dis*. 2014;33(9):1467-75. doi: 10.1007/s10096-014-2098-7. PubMed PMID: 24715155.
46. Giles BM, Boackle SA. Linking complement and anti-dsDNA antibodies in the pathogenesis of systemic lupus erythematosus. *Immunol Res*. 2013;55(1-3):10-21. doi: 10.1007/s12026-012-8345-z. PubMed PMID: 22941560; PubMed Central PMCID: PMC4018221.
47. Bruhns P. Properties of mouse and human IgG receptors and their contribution to disease models. *Blood*. 2012;119(24):5640-9. doi: 10.1182/blood-2012-01-380121. PubMed PMID: 22535666.
48. Hussain K, Hargreaves CE, Roghanian A, Oldham RJ, Chan HT, Mockridge CI, et al. Upregulation of Fc γ R2b on monocytes is necessary to promote the superagonist activity of TGN1412. *Blood*. 2015;125(1):102-10. doi: 10.1182/blood-2014-08-593061. PubMed PMID: 25395427.

2. ภาคผนวก (Appendix) ถ้ามี่

3. ประวัตินักวิจัยและคณะ พร้อมหน่วยงานสังกัด

ส่วน ค: ประวัติคณะผู้วิจัย

หัวหน้าโครงการ

1.ชื่อ - นามสกุล (ภาษาไทย) : นาย อัสฎาศ์ ลีฬหวนิชกุล

ชื่อ - นามสกุล (ภาษาอังกฤษ) Mr. Asada Leelahavanichkul

2.เลขหมายบัตรประจำตัวประชาชน 3100601653835

ตำแหน่งปัจจุบัน ผศ.

เงินเดือน 55,000 (บาท)

เวลาที่ใช้ทำวิจัย 40 (ชั่วโมง : สัปดาห์)

ฝ่ายวิจัย คณะแพทยศาสตร์ จุฬาลงกรณ์มหาวิทยาลัย

ตึก อปร. ชั้น 7 ถ.อังรีดูนัง ปทุมวัน กรุงเทพฯ 10330

โทรศัพท์ 081-714-9750

E-mail: a_leelahavanit@yahoo.com

4.ประวัติการศึกษา

2553	ดุษฎีบัณฑิต บัณฑิตวิทยาลัย จุฬาลงกรณ์มหาวิทยาลัย ประเทศไทย
2548-2553	Visiting fellow National institute of Health (NIH), Maryland, USA
2547	Board of Nephrology จุฬาลงกรณ์มหาวิทยาลัย ประเทศไทย
2545	Board of Internal Medicine จุฬาลงกรณ์มหาวิทยาลัย ประเทศไทย
2539	แพทยศาสตรบัณฑิต (เกียรตินิยม) จุฬาลงกรณ์มหาวิทยาลัย ประเทศไทย

5.สาขาวิชาการที่มีความชำนาญพิเศษ

โรคไตวายจากภาวะติดเชื้อในกระแสเลือด

6.ประสบการณ์ที่เกี่ยวข้องกับการบริหารงานวิจัยทั้งภายในและภายนอกประเทศ

โดยระบุสถานภาพในการทำการวิจัยว่าเป็นผู้อำนวยการแผนงานวิจัย หัวหน้าโครงการวิจัย หรือผู้ร่วมวิจัยในแต่ละผลงานวิจัย

7.ผู้อำนวยการแผนงานวิจัย: ชื่อแผนงานวิจัย -

7.1หัวหน้าโครงการวิจัย: ชื่อโครงการวิจัย Systems biology of aberrant targeting and polarization of membrane proteins in disease

7.2งานวิจัยที่ทำเสร็จแล้ว: ชื่อผลงานวิจัย ปีที่พิมพ์ การเผยแพร่ และแหล่งทุน (อาจมากกว่า 1 เรื่อง)

1. Dear JW, Leelahavanichkul A, Aponte A, Hu X, Constant SL, Hewitt SM, Yuen PS and Star RA. Liver proteomics for therapeutic drug discovery: inhibition of the cyclophilin receptor CD147

attenuates sepsis-induced acute renal failure. *Crit Care Med* 2007 Oct; 35(10):2319-28. (impact factor 6.5)

2. Yasuda H*, Leelahavanichkul A*, Tsunoda S, Dear JW, Takahashi Y, Ito S, Hu X, Zhou H, Doi K, Childs RW, Klinman DM, Yuen PS and Star RA. Chloroquine and inhibition of Toll-like receptor 9 protect from sepsis-induced acute kidney injury. *Am J Physiol Renal Physiol*. 2008 May; 294(5):F1050-8. (* distribution equally) (impact factor 4.6-5)

3. Leelahavanichkul A, Yasuda H, Doi K, Yuen PS, Hu X, Zhou H, Yuen PS and Star RA. Methyl-2-acetamidoacrylate decrease sepsis induced acute kidney injury in CD-1 mice. *Am J Physiol Renal Physiol*. 2008 Dec; 295(6):F1825-35. (impact factor 4.6-5)

4. Nemeth K*, Leelahavanichkul A *, Yuen PS, Mayer B, Parmelee B, Doi K, Robey P.G., Leelahavanichkul K, Hu X, Star RA and Mezey E. Bone marrow stromal cells significantly attenuate mouse poly-microbial sepsis via monocyte/macrophage derived IL-10. *Nature Medicine*. 2009 Jan; 15(1):42-9. (* distribution equally) (impact factor 27.1)

5. Leelahavanichkul A, Yan Q, Hu X, Eisner C, Huang Y, Chen R, Mizel D, Zhou H, Wright EC, Kopp JB, Schnermann J, Yuen PS, Star RA. Angiotensin II overcomes strain-dependent resistance of rapid CKD progression in a new remnant kidney mouse model. *Kidney Int* 2010 Dec; 78(11): 1136-53. (impact factor 6.4)

17. Leelahavanichkul A, Huang Y, Hu X, Zhou H, Tsuji T, Kopp JB., Schnermann J, Yuen ST, Star RA. Chronic kidney disease-induced splenic apoptosis and HMGB1 elevation worsens sepsis and sepsis-induced acute kidney injury *Kidney Int* 2011; Dec; 80(11):1198-211. (impact factor 6.4)

7. Leelahavanichkul A, Bocharov AV, Kurlander R, Baranova IN, Vishnyakova TG, Hu X, Doi K, Csako G, Yuen ST, Star RA, Eggerman TL. Class B Scavenger Receptor Types I and II and CD36 Targeting Improves Sepsis Survival and Acute Outcomes in Mice. *J Immunol*. 2012 Mar 15;188(6):2749-58. (impact factor 5.74)

8. Leelahavanichkul A, Sauza A, Hsu V, Zhou H, Eisner C, Li L, Hu X, Tsuji T, Kent D, Schnermann J, Yuen ST, Star RA. Serum Cystatin C as the marker of sepsis induce acute kidney injury in CD-1 mice; the usefulness and the limitation. *Am J Physiol Renal Physiol*. 2014 Aug; F939-F948. (impact factor 3.79)

9. Leelahavanichkul A, Somparn P, Panich T, Chanchaoenthana W, Wongphom J, Pisitkun T, Hirankarn N, Eiam-Ong S. The levels of serum microRNA-122 in acute liver injury induced by kidney injury and sepsis in CD-1 mouse models. *Hepato Res.* 2015 Dec; 45 (13): 1341-52. (impact factor 2.28)
10. Worasilchai N*, Leelahavanichkul A*, Kanjanabuch T, Thongbor N, Lorvinitnun P, Sukhontasing K, Finkelman M, Chindamporn A. (1→3)- β -D-glucan and galactomannan testing for the diagnosis of fungal peritonitis in peritoneal dialysis patients, a pilot study. *Med Mycol.* 2015 May 1;53(4):338-46. (* distribution equally) (impact factor 2.34)
11. Leelahavanichkul A, Somparn P, Bootprapan T, Tu H, Tangtanatakul P, Nuengjumnong R, Worasilchai N, Tiranathanagul K, Eiam-Ong S, Levine M, Chinampon A, Srisawat N. High-dose ascorbate with low-dose amphotericin B attenuates severity of disease in a model of re-appearance of candidemia during sepsis in the mouse. *Am J Physiol Regul Integr Comp Physiol.* 2015 Aug 1; 309(3): R223-34 (impact factor 3.66)
12. Leelahavanichkul A, Pongpirul K, Thongbor N, Worasilchai N, Petphuak K, Thongsawang B, Towannang P, Lorvinitnun P, Sukhontasing K, Katavetin P, Praditpornsilpa K, Eiam-Ong S, Chindamporn A, Kanjanabuch T. (1→3)- β -D-glucan and galactomannan for a differentiation of chemical "black particles" and fungal particles inside peritoneal dialysis tubing. *Perit Dial Int.* 2016; Jul-Aug;36(4):402-9. (impact factor 2.2)
13. Leelahavanichkul A, Somparn P, Issara-Amphorn J, Eiam-ong S, Avihingsanon Y, Hirankarn N, Srisawat N. Advantage of serum neutrophil gelatinase associated lipocalin in sepsis, impact of bilateral nephrectomy and bilateral ureter obstruction mouse models. *Shock.* 2016 May; 45 (5): 570-6 (impact factor 3.2)
13. Leelahavanichkul A, Worasilchai N, Wannalerdsakun S, Jutivorakool K, Somparn P, Issara-Amphorn J, Tachaboon S, Srisawat N, Finkelman M, Chindamporn A. Gastrointestinal Leakage Detected by Serum (1→3)- β -D-Glucan in Mouse Models and a Pilot Study in Patients with Sepsis. *Shock.* 2016 Nov;46(5):506-518. (impact factor 3.2)
14. Leelahavanichkul A, Panpetch W, Worasilchai N, Somparn P, Chanchaoenthana W, Nilgate S, Finkelman M, Chindamporn A, Tumwasorn S. Evaluation of gastrointestinal leakage using serum

(1→3)- β -D-glucan in a *Clostridium difficile* murine model. *FEMS Microbiol Lett.* 2016 Aug 28 (impact factor 2.0)

15. Ondee T, Surawut S, Taratummarat S, Hirankan N, Palaga T, Pisitkun P, Pisitkun T, Leelahavanichkul A*. Fc gamma receptor IIb deficient mice: A lupus model with increased endotoxin tolerance-related sepsis susceptibility. *Shock.* 2016 Jun;47(6):743-752. (impact factor 3.2)>(* correspondence author)

16. Surawut S, Ondee T, Taratummarat S, Palaga T, Pisitkun P, Chindamporn A, Leelahavanichkul A*. The role of macrophages in the susceptibility of Fc gamma receptor IIb deficient mice to *Cryptococcus neoformans*. *Sci Report.* 2016 Jan 11;7:40006. (Accepted) (impact factor 5.5)(* correspondence author)

17. Rattanasinganchan P, Sopotthummakhun K, Doi K, Hu X, Payne MD, Pisitkun T, Leelahavanichkul A*. Folic acid-induced rat kidney fibrosis: preliminary evaluation as a potential model for identification of fibrosis biomarkers from urinary exosomes. *Asian BioMed* 2016 (Accepted) (impact factor 0.134)>(* correspondence author)

18. Leelahavanichkul A, Chanchaoenthana W, Wongphom J, Eiam-Ong S, Srisawat N. Mouse chronic renal ischemic reperfusion injury model of chronic tubulointerstitial kidney disease, suitable model for urinary exosome experiments. *Asian BioMed* 2016 (Accepted) (impact factor 0.134)

19. Panich T, Chanchaoenthana W, Somparn P, Issara-Amphorn J, Hirankarn N, Leelahavanichkul A*. Urinary Exosomal Activating Transcriptional Factor 3 as the Early Diagnostic Biomarker for Sepsis-Induced Acute Kidney Injury. *BMC Nephrology.* 2016 (Accepted) (impact factor 2.2)>(* correspondence author)

20. Cannizzaro L, Rossoni G, Savi F, Altomare A, Marinello C, Saethang T, Carini M, Payne MD, Pisitkun T, Aldini G, Leelahavanichkul A*. Regulatory landscape of AGE-RAGE-oxidative stress axis and its modulation by PPAR γ activation in high fructose diet-induced metabolic syndrome. *Nutrition & Metabolism.* 2016 (Accepted) (impact factor 3.2)(* correspondence author)

21. Panpetch W, Somboonna N, Bulan DE, Issara-Amphorn J, Worasilchai N, Finkelman M, Chindamporn A, Palaga T, Tumwasorn S, Leelahavanichkul A*. Gastrointestinal Colonization of *Candida Albicans* Increases Serum (1→3)- β -D-Glucan, without Candidemia, and Worsens Cecal

Ligation and Puncture Sepsis in Murine Model. Shock. 2017 May 11. (impact factor 3.2)>(* correspondence author)

22. Panpetch W, Somboonna N, Bulan DE, Issara-Amphorn J, Finkelman M, Worasilchai N, Chindamporn A, Palaga T, Tumwasorn S, Leelahavanichkul A. Oral administration of live- or heat-killed *Candida albicans* worsened cecal ligation and puncture sepsis in a murine model possibly due to an increased serum (1 \rightarrow 3)- β -D-glucan. PLoS One. 2017 Jul 27;12(7):e0181439. (impact factor 2.8)>(* correspondence author)

23. Panpetch W, Chancharoenthana W, Bootdee K, Nilgate S, Finkelman M, Tumwasorn S, Leelahavanichkul A. *Lactobacillus rhamnosus* L34 attenuates gut translocation induced bacterial sepsis in murine models of leaky gut. Infect Immun. 2017 Dec 19;86(1). pii: e00700-17. (impact factor 3.731) (* correspondence author)

24. Issara-Amphorn J, Surawut S, Worasilchai N, Thim-uam A, Finkelman M, Chindamporn A, Palaga T, Hirankarn N, Pisitkun P, Leelahavanichkul A*. Synergy of endotoxin and (1-3)- β -D-glucan, from gut translocation, worsens sepsis severity in a lupus model of Fc gamma receptor IIb deficient mice. Journal of innate immunity, accepted (impact factor 4.1) (* correspondence author)

25. Chancharoenthana W, Leelahavanichkul A*, Taratummarat S, Wongphom J, Tiranathanagul K, Eiam-Ong S. Cilostazol attenuates intimal hyperplasia in a mouse model of chronic kidney disease. PLoS One. 2017 Dec 5;12(12):e0187872. (impact factor 2.8) (* correspondence author)

26. Surawut S, Panpetch W, Makjaroen J, Tangtanatakul P, Thim-Uam A, Wongphoom J, Tumwasorn S, Leelahavanichkul A*. *Helicobacter pylori* Infection Increased Anti-dsDNA and Enhanced Lupus Severity in Symptomatic Fc γ RIIb-Deficient Lupus Mice. Front Microbiol. 2018 Jul 6; 9:1488. (impact factor 4.3)(* correspondence author)

27. Wirapakorn C, Klaewsongkram J, Singkham-In U, Taratummarat S, Surawut S, Visitchanakun P, Chatsuwan T, Leelahavanichkul A*. The cooperation of pharmacologic-dose ascorbate with ceftriaxone against *Staphylococcus aureus* through bactericidal synergy and enhanced macrophage killing activity. Asian Pac J Allergy Immunol. 2018 Aug 13. . (impact factor 1.01) (*correspondence author)

7.3งานวิจัยที่กำลังทำ: ชื่อข้อเสนอการวิจัย แหล่งทุน และสถานภาพในการทำวิจัยว่าได้ทำการวิจัย ลุล่วงแล้วประมาณร้อยละเท่าใด

ชื่อข้อเสนอการวิจัย Mechanisms of exhaustion of Fc γ RIIB^{-/-} macrophage

แหล่งทุน Health cluster

การวิจัยลู่วงแล้วประมาณร้อยละ 50

ชื่อข้อเสนอการวิจัย Role of gut leakage in thalassemia

แหล่งทุน สวทช.

การวิจัยลู่วงแล้วประมาณร้อยละ 25